CG
ABUS icon

Cutler Group’s Arbutus Biopharma ABUS Stock Holding History

Cutler Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21,400
Closed -$19K – 5208
2021
Q4 		$19K Buy
+21,400
New +$83.1K ﹤0.01% 3148
2019
Q2 		– Sell
-6,000
Closed -$10K – 4132
2019
Q1 		$10K Buy
+6,000
New +$23K ﹤0.01% 2463
2018
Q4 		– Sell
-8,000
Closed -$3K – 3841
2018
Q3 		$3K Buy
+8,000
New +$79.4K ﹤0.01% 3273
2017
Q2 		– Sell
-4,300
Closed -$1K – 6263
2017
Q1 		$1K Sell
4,300
-25,600
-86% -$71K ﹤0.01% 5722
2016
Q4 		$7K Buy
29,900
+20,600
+222% +$59.9K ﹤0.01% 4549
2016
Q3 		$4K Buy
9,300
+3,400
+58% +$13.3K ﹤0.01% 5078
2016
Q2 		$4K Buy
5,900
+4,500
+321% +$19K ﹤0.01% 5062
2016
Q1 		$2K Buy
1,400
+300
+27% +$1.07K ﹤0.01% 5474
2015
Q4 		$19K Buy
+1,100
New +$6.03K ﹤0.01% 3440

Other funds holding ABUS

WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cutler Group's ABUS Position: Q1 2024 in Review

Cutler Group sold out of Arbutus Biopharma (ABUS) in Q1 2024, closing a stake of 4,500 shares — an estimated $11K sold.

Cutler Group first reported a position in ABUS in Q4 2015 and held it in 27 quarters. The position peaked at $93K in Q1 2017. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2024.

  • Cutler Group reported no remaining Arbutus Biopharma position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 4,500 Arbutus Biopharma shares in Q1 2024, an estimated $11K.
  • Cutler Group first reported a position in Arbutus Biopharma in Q4 2015 and held it in 27 quarters.
  • Cutler Group's Arbutus Biopharma position peaked at $93K in Q1 2017.
  • 119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.